Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Pharmacology of basimglurant (RO4917523
50 uM/20uM compound concentration's inhibitory percentage are 98%/92% for chitinase/N- acetyl-hexosaminidase respectively
Mice are treated with FIDAS-5 (20 mg/kg) for 1 week
WAY-200070 (30 mg/kg s
PF-06463922 5109 HCl Pharmacology of basimglurant (RO4917523Lorlatinib, also known as PF 06463922, is an orally available, ATP competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, ALK ROS1 inhibitor PF 06463922 binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK and ROS1 mediated signaling and eventually inhibits tumor cell growth in ALK and
US$ 140.00
US$ 85.00
US$ 105.00
US$ 130.00
US$ 90.00
US$ 45.99
US$ 180.00
US$ 149.97